Open AccessBenefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
Author(s) -
Gary E. Raskob,
Walter Ageno,
Gregory W. Albers,
C. Gregory Elliott,
Jonathan L. Halperin,
Gregory Maynard,
Philippe Gabriel Steg,
Jeffrey I. Weitz,
John Albanese,
Zuyi Yuan,
Bennett Levitan,
Wentao Lu,
Eun Young Suh,
Theodore E. Spiro,
Concetta Lipardi,
Elliot S. Barnathan,
Alex C. Spyropoulos
Publication year - 2022
Publication title -
journal of the american heart association. cardiovascular and cerebrovascular disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.122.026229
Subject(s) - medicine , rivaroxaban , population , placebo , venous thromboembolism , pulmonary embolism , intensive care medicine , emergency medicine , randomized controlled trial , warfarin , thrombosis , atrial fibrillation , alternative medicine , environmental health , pathology